Lancet Neurology

Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Genetics

New genetic clues point to new treatments for 'silent' stroke

Scientists have identified new genetic clues in people who've had small and often apparently 'silent' strokes that are difficult to treat and a major cause of vascular dementia, according to research funded by the British ...

Neuroscience

Aspirin not as effective as anticoagulation

In a multicenter study led by the University Hospital and the University Geriatric Medicine FELIX PLATTER Basel, a research group with participation from University of Basel, Inselspital, Bern University Hospital, the University ...

Neuroscience

Disorders in movement

Spinocerebellar ataxias are diseases of the nervous system associated with a loss of motor coordination. A European research alliance headed by the German Center for Neurodegenerative Diseases (DZNE) and the University of ...

Medications

Antidepressant does not improve post-stroke recovery

The antidepressant fluoxetine has been suggested as a means to improve brain recovery after acute stroke. However, a large randomized study on stroke patients at 35 Swedish hospitals shows that the drug has no such effect. ...

Genetics

Huntington disease brain changes ID'd 24 years before symptoms

(HealthDay)—The earliest brain changes due to Huntington disease (HD) can be detected in cerebrospinal fluid (CSF) 24 years before clinical symptoms show, according to a study published in the June 1 issue of The Lancet ...

page 9 from 21